← FDA DRUG APPROVALS

FDA ANDA · ANDA210213

ALOGLIPTIN

Sponsor: MSN LABS PVT LTD

APPLICATION
ANDA210213
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

ALOGLIPTINNone (Tentative Approval)
ALOGLIPTIN BENZOATE EQ 12.5MG BASE · TABLET · ORAL
ALOGLIPTINNone (Tentative Approval)
ALOGLIPTIN BENZOATE EQ 25MG BASE · TABLET · ORAL
ALOGLIPTINNone (Tentative Approval)
ALOGLIPTIN BENZOATE EQ 6.25MG BASE · TABLET · ORAL

Approval history

2019-01-29UNKNOWN · Original · standard — Letter ↗TA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →